Proton Therapy Switzerland
Reviewed by the SwissAtlas coordination team · Last updated:
Oncology file construction and chronology discipline guides the way families prepare high-stakes decisions under cross-border pressure.
Reviewed by the SwissAtlas coordination team · Last updated:
Oncology file construction and chronology discipline guides the way families prepare high-stakes decisions under cross-border pressure.
Proton therapy delivers radiation using protons rather than photons. The physical advantage is the Bragg peak: protons deposit the bulk of their dose at a controlled depth, with a rapid fall-off beyond the target volume and minimal exit dose. This dose distribution is most relevant when critical structures — optic apparatus, brainstem, cochlea, salivary glands, spinal cord — sit immediately adjacent to the tumour volume, because it reduces the dose received by surrounding tissue compared with photon radiotherapy plans.
Cancer treatment coordination in Switzerland aligns with research frameworks maintained by Swiss Cancer Research.
The clinical advantage of protons over photons is not universal. It is strongest in specific anatomical and biological conditions. For many tumour types and locations, modern photon techniques — IMRT, VMAT, stereotactic radiotherapy — achieve comparable dose distributions. Families should not assume proton therapy is superior without a formal dosimetric comparison, which PSI conducts as part of its evaluation process.
SwissAtlas supports international families navigating complex medical situations with discretion and clarity. Each case is handled with strict confidentiality and a structured coordination approach. Designed for sensitive situations requiring discretion and clarity.
Switzerland's proton therapy centre is the Paul Scherrer Institut (PSI) in Villigen, Canton Aargau — one of the longest-operating proton facilities in the world, with a programme history extending over three decades. Primary indications where proton therapy offers the strongest evidence base include: paediatric tumours (medulloblastoma, ependymoma) where late radiation effects on developing tissue are a primary concern; skull-base tumours (chordoma, chondrosarcoma) adjacent to optic apparatus and brainstem; head and neck cases in re-irradiation settings where prior photon exposure has already consumed tolerance in critical structures; selected prostate cases; and ocular melanoma, where PSI has a long-standing specialised programme.
Candidacy requires a formal dosimetric comparison with conventional radiotherapy plans. This comparison is conducted by the PSI proton therapy team based on submitted imaging and treatment history. It is not a formality — some patients who enquire about proton therapy are not candidates once the dosimetric evaluation is complete. Early file submission for technical screening is therefore the first practical step, not travel booking.
Proton therapy at PSI requires the longest sustained Switzerland presence of any modality on this site. Standard treatment courses run 15 to 35 fractions depending on indication and fractionation design, which translates to a three to seven week in-country stay with daily weekday attendance. Families should plan accommodation near the facility — PSI is accessible from Baden (15 minutes) or Zurich (35 minutes) — with flexibility built in for schedule adjustments due to machine maintenance or medical review.
Total cost for a full proton therapy course at PSI typically ranges from CHF 80,000 to CHF 180,000 depending on indication complexity and fractionation schedule. This figure covers the treatment course itself; concurrent systemic therapy, if prescribed, generates separate costs managed through the patient's oncology team. Pre-treatment evaluation, which may require one to three weeks for the dosimetric assessment, should be budgeted as a separate phase.
PSI requires complete staging documentation before the dosimetric comparison can be conducted. This includes: recent contrast-enhanced MRI or CT in native DICOM format (not JPEG exports), prior radiotherapy records with dose-volume histograms where prior irradiation has occurred, full pathology report with molecular data where relevant, and a complete treatment chronology. Missing components delay the evaluation, which delays the entire pathway. File completeness at submission is the single most controllable variable in proton therapy timeline management.
Families coordinating this pathway should not book travel until PSI has confirmed candidacy in writing. The evaluation phase is a clinical decision, not an administrative step, and its outcome is not guaranteed. Planning around an assumed positive result is the most common source of costly disruption in proton therapy cases.
Some proton therapy protocols involve concurrent systemic therapy — chemotherapy or targeted agents administered during the radiotherapy course. When this is the case, coordination between the referring oncologist's systemic therapy schedule and the PSI fractionation schedule must be agreed among three parties: the referring oncologist, the PSI proton team, and the patient's Swiss-based internist or haematologist. This multi-institutional coordination is where proton therapy cases become operationally complex, and where a single non-clinical coordination point materially reduces friction and documentation gaps.
SwissAtlas operates exclusively as a non-medical coordination platform. We do not provide clinical services, diagnoses, or treatment recommendations. All medical decisions are made by licensed Swiss institutions.
Proton therapy requires the longest sustained presence in Switzerland of any treatment modality on this site. A standard course of 20–35 fractions means three to seven weeks of daily weekday attendance at PSI in Villigen, Canton Aargau. Families should plan accommodation near the facility (Villigen is accessible from Baden or Zurich) for the patient and accompanying family member, with enough flexibility to accommodate potential schedule adjustments — machine maintenance and medical reviews can shift treatment days.
The candidacy evaluation at PSI begins with an external file review before any travel is arranged. The team at PSI reviews imaging, pathology, and prior treatment history to determine whether proton therapy offers a meaningful dosimetric advantage over photon radiotherapy for the specific case. This review is conducted by the institution's proton therapy team, not by SwissAtlas — SwissAtlas facilitates the submission of the file and the communication loop. The evaluation typically takes one to three weeks; families should not make travel arrangements until candidacy is confirmed.
Concurrent systemic therapy during proton therapy — chemotherapy or targeted agents — is sometimes part of the treatment plan. If the patient's oncologist recommends concurrent treatment, the coordination between the systemic therapy schedule and the proton fractionation schedule must be agreed between the referring oncologist, the PSI team, and the patient's Swiss-based internist or haematologist. This multi-institutional coordination is where proton therapy cases become logistically complex, and where a single operational coordinator materially reduces the friction.
SwissAtlas coordinates non-clinical sequencing, documentation flow, and logistics governance while licensed institutions retain medical decision authority.
Records should be assembled as chronology with unresolved questions so specialist review can proceed without avoidable interpretation gaps.
Budgets should be scenario-based because pathway scope can evolve after deeper institutional evidence review.
Confidentiality is strengthened by role-based recipient controls and approved channels defined before high-sensitivity updates begin.
Timelines are safer when logistics commitments are tied to confirmed milestones rather than assumptions made before candidacy is established.
Confidential access to private medical care in Switzerland.
SwissAtlas operates at the intersection of discretion, structure, and access. Unlike traditional intermediaries, we do not promote specific clinics or treatments. Our role is to provide a neutral, structured, and confidential coordination layer for international patients navigating complex medical situations. This approach allows families to move forward with clarity, without pressure, and without exposure.
SwissAtlas is designed for: international families seeking discretion; patients requiring fast and structured access; situations where clarity and confidentiality are essential.
No medical advice. No pressure. Only structured coordination.
For the complete strategic framework, review medical travel in Switzerland, treatment in Switzerland for international patients, and private healthcare Switzerland.